ARTA
VRDN icon

A.R.T. Advisors’s Viridian Therapeutics VRDN Stock Holding History

A.R.T. Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,107
Closed -$18K – 258
2020
Q2 		$18K Buy
+1,107
New +$12.6K 0.03% 262
2019
Q4 		– Sell
-1,430
Closed -$16K – 1759
2019
Q3 		$16K Buy
1,430
+516
+56% +$11.4K ﹤0.01% 1377
2019
Q2 		$28K Buy
+914
New +$36.7K ﹤0.01% 1280

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

A.R.T. Advisors's VRDN Position: Q3 2020 in Review

A.R.T. Advisors sold out of Viridian Therapeutics (VRDN) in Q3 2020, closing a stake of 1,107 shares — an estimated $18K sold.

A.R.T. Advisors first reported a position in VRDN in Q2 2019 and held it in 3 quarters. The position peaked at $28K in Q2 2019. 26 funds tracked by Wall St. Rank hold VRDN as of Q3 2020.

  • A.R.T. Advisors reported no remaining Viridian Therapeutics position as of Q3 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 1,107 Viridian Therapeutics shares in Q3 2020, an estimated $18K.
  • A.R.T. Advisors first reported a position in Viridian Therapeutics in Q2 2019 and held it in 3 quarters.
  • A.R.T. Advisors's Viridian Therapeutics position peaked at $28K in Q2 2019.
  • 26 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2020.

Based on A.R.T. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.